Technical Update, Leadership Appointments, and Clinical Trial Results - Analyst Notes on Achillion, Nektar, CytRx, Galena and Receptos

NEW YORK, June 12, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN), Nektar Therapeutics (NASDAQ: NKTR), CytRx Corporation (NASDAQ: CYTR), Galena Biopharma, Inc. (NASDAQ: GALE) and Receptos, Inc. (NASDAQ: RCPT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3633-100free.

--
Achillion Pharmaceuticals, Inc. Analyst Notes
On June 9, 2014, Achillion Pharmaceuticals, Inc. (Achillion) stock marked a 47.57% gain, ending trading at $4.25. The Company's stock increased 56.83% over the past three trading days compared to the Nasdaq Composite which rose 1.99% a during the same trading period. The full analyst notes on Achillion are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/ACHN/report.pdf

--
Nektar Therapeutics Analyst Notes
On May 19, 2014, Nektar Therapeutics (Nektar) announced the appointment of Ivan Gergel, M.D. as the Company's Senior Vice President, Drug Development & CMO, effective immediately. In his new role, Dr. Gergel will be responsible in overseeing the Company's clinical strategy and activities including direct supervision of clinical research, clinical operations, medical affairs, regulatory affairs, and drug safety and surveillance. Howard W. Robin, President and CEO of Nektar said, "Throughout his career, Ivan has consistently demonstrated both leadership and expertise in drug development, including the advancement of multiple CNS and pain compounds from research stages through approval. He has an impressive track record with extensive experience in all aspects of the clinical and regulatory process. Ivan's leadership skills and experience will be invaluable to Nektar as we advance the development of our proprietary pipeline." The full analyst notes on Nektar are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/NKTR/report.pdf

--
CytRx Corporation Analyst Notes
On May 28, 2014, CytRx Corp. (CytRx) announced results from an ongoing open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). Results showed that aldoxorubicin increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. Steven A. Kriegsman, CytRx President and CEO said, "We look forward to discussing the data with the oncology community and to reporting the full overall survival results from this trial in the second half of 2014. In parallel, we continue to actively enroll patients in our pivotal global Phase 3 trial in second-line STS. In that Phase 3 clinical trial, we are permitted to dose until progression, which could substantially enhance the benefit for sarcoma patients." The full analyst notes on CytRx are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/CYTR/report.pdf

--
Galena Biopharma, Inc. Analyst Notes
On June 2, 2014, Galena Biopharma, Inc. (Galena) announced that data from its Phase 1 study with GALE-301, or Folate Binding Protein (FBP) was presented at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting with a poster entitled "Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy." According to the Company, a total of 30 patients were enrolled in the Phase 1 trial and out of 14 control patients, 7 (50%) have recurred; of 16 vaccinated patients, 4 (25%) have recurred after completing the primary vaccine series (PVS), 2 (12.5%) recurred prior to completing the PVS, and one patient withdrew. "These promising initial results demonstrate the vaccine is dose responsive with the immune system and we are encouraged about the potential for this compound to prevent recurrence in women suffering from high risk gynecological cancers where current treatment options are limited," said Mark J. Ahn, Ph.D., President and CEO. "The data from this study served as the basis for advancing GALE-301 into its ongoing Phase 2 trial that includes a booster regimen. We expect enrollment in this trial to complete shortly, ahead of schedule." The full analyst notes on Galena are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/GALE/report.pdf

--
Receptos, Inc. Analyst Notes
On June 9, 2014, Receptos, Inc. (Receptos) announced positive results from the Phase 2 RADIANCE trial of RPC1063 in relapsing multiple sclerosis (RMS). According to the Company, the trial met its primary efficacy endpoint with statistical significance after 24 weeks of treatment "The positive results of the Phase 2 portion of RADIANCE exceeded our expectations with respect to the differentiation thesis for RPC1063," said Faheem Hasnain, President and CEO of Receptos. "Based on our analysis of the Phase 2 dataset, we believe that RPC1063 has the opportunity to be the best-in-class S1P receptor modulator. Our Phase 3 program is now well underway, positioning the program as the most advanced S1P receptor modulator in development for relapsing multiple sclerosis. In addition, we believe that RPC1063 may have promise in other therapeutic areas, and we continue to look forward to the results of TOUCHSTONE, our Phase 2 trial of RPC1063 in ulcerative colitis, in the fourth quarter of 2014." The full analyst notes on Receptos are available to download free of charge at:

http://www.analystsreview.com/Jun-12-2014/RCPT/report.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review